Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma
Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. OncoTargets and Therapy. 9:773-780.